Trial Profile
A phase II trial of agalsidase beta (ISU303) for the treatment of Fabry's disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2015
Price :
$35
*
At a glance
- Drugs Agalsidase beta (Primary)
- Indications Fabry's disease
- Focus Therapeutic Use
- 27 Apr 2015 New trial record